Advanced Biomed Inc. (NASDAQ:ADVB) Short Interest Up 441.2% in July

Advanced Biomed Inc. (NASDAQ:ADVB) saw a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 57,213 shares, an increase of 441.2% from the July 15th total of 10,571 shares. Based on an average trading volume of 8,635,838 shares, the days-to-cover ratio is presently 0.0 days. Approximately 4.7% of the shares of the company are short sold.

Hedge Funds Weigh In On Advanced Biomed

An institutional investor recently bought a new stake in Advanced Biomed stock. GSA Capital Partners LLP purchased a new position in shares of Advanced Biomed Inc. (NASDAQ:ADVB) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 193,323 shares of the company’s stock, valued at approximately $599,000. GSA Capital Partners LLP owned approximately 11.70% of Advanced Biomed as of its most recent filing with the Securities and Exchange Commission (SEC).

Advanced Biomed Price Performance

NASDAQ ADVB opened at $7.77 on Wednesday. The company’s 50-day moving average is $6.57. The stock has a market cap of $12.84 million, a price-to-earnings ratio of 1.61 and a beta of -0.41. Advanced Biomed has a fifty-two week low of $3.61 and a fifty-two week high of $24.23.

Advanced Biomed (NASDAQ:ADVB) last issued its earnings results on Saturday, May 16th. The company reported ($0.38) EPS for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Advanced Biomed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 23rd. One analyst has rated the stock with a Sell rating, According to MarketBeat, Advanced Biomed presently has a consensus rating of “Sell”.

Advanced Biomed Company Profile

Our Mission We are committed to the application research of integrating semiconductor technology and biotechnology. Through the enrichment, capture, and identification of circulating tumor cells and related tumor marker cells in the field of liquid biopsy, we aim to provide cancer patients with rapid and affordable assay products and services. These services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer. We are a holding company incorporated in the State of Nevada.